Indoco Remedies Limited informed the stock exchanges that its Plant II and Plant III facility, located at Verna Industrial Estate in Goa, received a warning letter from the US Food and Drug Administration (USFDA) on December 17, 2024.
This action follows an earlier inspection conducted by the USFDA from July 16 to July 26, 2024, and the Official Action Indicated (OAI) status communicated to the company on October 11, 2024.
Despite this regulatory setback, Indoco Remedies remains committed to addressing the concerns raised. The company has assured stakeholders of its cooperation with the USFDA to resolve the issues at the earliest. Indoco also emphasised that quality and compliance with Current Good Manufacturing Practices (CGMP) remain its top priorities.
The company stated that it continues to supply products from the affected facility to fulfil commitments to its customers and patients in the United States.
Following this development, the share price of Indoco Remedies tumbled by 1.78% as of 12:58 PM on December 17, 2024.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
